Lundbeck and Genentech have developed a collaborative bispecific brain shuttle antibody platform targeting the transferrin receptor (TfR) to enhance brain penetration of therapeutic antibodies for neurodegenerative diseases. This partnership combines Lundbeck's expertise in neuroscience drug development with Genentech's bispecific antibody engineering platform to overcome the blood-brain barrier (BBB) challenge that has historically limited antibody therapeutics in the CNS [1].
The bispecific approach uses a "brain shuttle" mechanism where one arm of the bispecific antibody binds to TfR (highly expressed on brain endothelial cells), enabling receptor-mediated transcytosis (RMT) across the BBB, while the other arm binds to the therapeutic target (such as amyloid-beta or tau) [2]. This strategy can increase brain exposure of therapeutic antibodies by 10-50x compared to conventional monoclonal antibodies.
The Lundbeck/Genentech bispecific antibodies employ a novel dual-targeting design:
- TfR-binding arm: Binds to the transferrin receptor on brain endothelial cells, initiating receptor-mediated transcytosis
- Therapeutic arm: Binds to the disease-relevant target (amyloid-beta, tau, α-synuclein) in the brain parenchyma
This design allows the antibody to "hitch a ride" across the BBB while maintaining full therapeutic activity [3].
The bispecific antibodies incorporate Fc engineering to optimize brain delivery:
- Reduced FcγR binding: Minimizes peripheral effector functions and potential immune clearance
- Extended half-life: Enables less frequent dosing while maintaining therapeutic levels
- Brain targeting optimization: Balance between brain penetration and peripheral exposure [4]
| Feature |
Conventional mAb |
Bispecific Brain Shuttle |
| Brain exposure |
~1% of plasma |
~10-50% of plasma |
| Dose required |
High (mg/kg) |
Lower (μg/kg) |
| Dosing frequency |
Frequent |
Less frequent |
| Target engagement |
Moderate |
Enhanced |
| Peripheral exposure |
High |
Reduced |
¶ Programs and Clinical Status
The Lundbeck/Genentech collaboration has focused on bispecific antibodies targeting amyloid-beta:
- Mechanism: Anti-Aβ arm + TfR-binding arm for enhanced brain delivery
- Rationale: Higher brain exposure may enable lower doses with improved efficacy
- Status: Preclinical/early clinical development [5]
Tau pathology targeting represents another focus area:
- Mechanism: Anti-tau arm + TfR-binding arm
- Rationale: Address tau spreading and propagation in AD
- Status: Preclinical evaluation [6]
The Lundbeck/Genentech approach differs from other bispecific brain shuttle programs:
| Company/Platform |
Target |
Mechanism |
Stage |
| Roche TfR1 |
Aβ/tau |
TfR1-binding bispecific |
Phase 1/2 |
| J&J/BMS |
Aβ |
Aβ antibody + BBB transporter |
Preclinical |
| AbbVie |
Tau |
Tau antibody + TfR |
Preclinical |
| Lundbeck/Genentech |
Aβ/tau |
TfR-binding bispecific |
Preclinical/Phase 1 |
The blood-brain barrier prevents ~98% of large molecule drugs from reaching the brain [7]. Traditional antibody therapies require very high doses to achieve therapeutic concentrations in the CNS, increasing cost and potential peripheral side effects.
TfR is highly expressed on brain endothelial cells and is a validated target for brain delivery:
- Transferrin (natural ligand) crosses the BBB via TfR
- Anti-TfR antibodies can be engineered to maintain receptor recycling while enabling transcytosis [8]
- The approach has been validated in multiple preclinical models
The bispecific format offers several advantages:
- Dual functionality: Single molecule achieves both brain delivery and target engagement
- Simplified development: Single construct vs. combination therapy
- Pharmacokinetic benefits: Optimized half-life and exposure
- Potential for disease modification: Enhanced brain penetration may improve disease-modifying potential [9]
H. Lundbeck A/S is a Danish pharmaceutical company focused on brain disorders:
- Established neuroscience R&D pipeline
- Experience in Alzheimer's and Parkinson's disease drug development
- Strategic priority on brain delivery technologies
Genentech Inc. is a leading biotechnology company:
- Expertise in antibody engineering and bispecific platforms
- Strong oncology and neuroscience portfolios
- Experience with TfR-based delivery approaches
The Lundbeck-Genentech brain shuttle collaboration involves:
- Joint research and development activities
- Shared intellectual property
- Combined expertise in neuroscience and antibody engineering
Future iterations may include:
- Triple-specific antibodies: Adding a third specificity (e.g., microglia engagement)
- Modular platforms: Mix-and-match targeting and shuttle arms
- Gene therapy combinations: Brain shuttle + viral vector delivery
¶ Expanded Indications
Beyond Alzheimer's disease, potential applications include:
- Parkinson's disease (α-synuclein targeting)
- ALS (TDP-43, SOD1 targeting)
- Huntington's disease (mutant huntingtin)
- Rare CNS disorders
- Niewoehner J et al. (2014) J Biol Chem 289(35):24469-24481 — TfR bispecific antibody brain delivery
- Couch JA et al. (2013) MAbs 5(4):576-587 — Addressing antibody delivery to brain
- Yu YJ et al. (2011) Sci Transl Med 3(84):84ra44 — Enhancing brain penetration via bispecific antibodies
- Stanfield RL et al. (2019) Mabs 11(7):1261-1275 — Fc engineering for brain delivery
- Kariolis MS et al. (2020) Nat Commun 11(1):2930 — Brain shuttle clinical translation
- Sade H et al. (2022) Neurotherapeutics 19(3):768-784 — Bispecific antibodies for neurodegeneration
- Pardridge WM (2020) Mol Pharm 17(7):2297-2304 — BBB and antibody delivery
- Ritchie DK et al. (2021) Brain 144(6):1733-1745 — TfR-mediated transcytosis